Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Asymptomatic left ventricular dysfunction

5

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Angiotensin-converting enzyme

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1985

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

5

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

SMS_ID

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ACE INHIBITORS, COMBINATIONS

1

ACE INHIBITORS, PLAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

ACE inhibitors and calcium channel blockers

1

ACE inhibitors and diuretics

1

ACE inhibitors, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ENALAPRILAT ANHYDROUS

Q508Q118JM

Export Data
Search for Structure

Status:

US Approved Rx (2000)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Asymptomatic left ventricular dysfunction

Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapri...

l, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.

ENALAPRILAT DIHYDRATE

GV0O7ES0R3

Export Data
Search for Structure

Status:

US Approved Rx (2000)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Asymptomatic left ventricular dysfunction

Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapri...

l, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.

ENALAPRIL MALEATE

9O25354EPJ

Export Data
Search for Structure

Status:

US Approved Rx (2000)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Asymptomatic left ventricular dysfunction

Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapri...

l, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.

ENALAPRIL SODIUM

94A7UFL2SI

Export Data
Search for Structure

Status:

US Approved Rx (2000)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Asymptomatic left ventricular dysfunction

Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapri...

l, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.

ENALAPRIL

69PN84IO1A

Export Data
Search for Structure

Status:

US Approved Rx (2000)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Asymptomatic left ventricular dysfunction

Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapri...

l, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1